CAR-NK cells: promising for cancer therapy
Drug Target Review
NOVEMBER 17, 2023
The relative ease and lower cost of manufacture (potentially a few thousand dollars) compared to autologous T cell therapies (hundreds of thousands of dollars), coupled with their functional attributes and safety profile, make NK cells an attractive therapeutic option for cancer patients, but surprisingly this is not universally recognised.
118 
Let's personalize your content